Apoptosis in primary cultures of E14 rat ventral mesencephala: Time course of dopaminergic cell death and implications for neural transplantation

Experimental Neurology

Volumn 160, Issue 1, 1999, Pages 88-98

  Branton, Richard L ^a   Clarke, Deborah J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apoptosis; Dopaminergic; Neural transplantation; Parkinson's disease; Primary culture; Time course

Indexed keywords

ACRIDINE ORANGE; ETHIDIUM BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL LOSS; CELL SURVIVAL; CELL SUSPENSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MESENCEPHALON; NERVE CELL CULTURE; NERVE CELL NECROSIS; NERVE FUNCTION; NERVE GRAFT; NERVE TRANSPLANTATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0032736041     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7207     Document Type: Article

References (72)

1. Annett L. E. Functional studies of neural grafts in parkinsonian primates. Dunnett S. B., Björklund A. Functional Neural Transplantation. 1994;71-102 Raven Press, New York.
2. Anton R., Kordower J. H., Kane D. J., Markham C. H., Bredesen D. E. Neural transplantation of cells expressing the anti-apoptotic gene bcl-2. Cell Transplant. 4:1995;49-54.
3. Backlund E.-O., Granberg P.-O., Hamberger B., Knutsson E., Mårtensson A., Sedvall G., Seiger A., Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62:1985;169-173.
4. Bakay R. A. E., Fiandaca M. S., Barrow D. L., Schiff A., Collins D. C. Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. Appl. Neurophysiol. 48:1985;358-361.
5. Barbeau A. Etiology of Parkinson's disease: A research strategy. Neurol. Sci. 11:1984;1124-1128.
6. Barbeau A., Cloutier R. T., Plasse L., Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. Adv. Neurol. 45:1986;299-306.
7. Barker R. A., Dunnett S. B., Faissner F., Fawcett J. W. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp. Neurol. 141:1996;79-93.
8. Barker R. A., Fricker R. A., Abrous D. N., Fawcett J. W., Dunnett S. B. A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures and in vivo grafts. Cell Transplant. 4:1994;173-200.
9. Ben Sasson S. A., Sherman Y., Gavrieli Y. Identification of dying cells - . Methods Cell Biol. 46:1995;29-39.
10. Björklund A. Better cells for brain repair. Nature. 362:1993;414-415.
11. Björklund A., Steveni U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177:1979;555-560.
12. Björklund L., Spenger C., Strömberg I. Tirilazad mesylate increases dopaminergic neuronal survival in the in oculo grafting model. Exp. Neurol. 148:1997;324-333.
13. Brewer G. J. Serum-free B27/Neurobasal medium supports differentiated growth of neurons from the striatum, substantia, nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J. Neurosci. Res. 42:1995;674-683.
14. Brundin P., Isacson O., Björklund A. Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res. 331:1995;251-259.
15. Brundin P., Strecker R., Widner H., Clarke D., Nilsson O., Åstedt B., Lindvall O., Björklund A. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Immunological aspects, spontaneous and drug-induced behaviour and dopamine release. Exp. Brain Res. 70:1988;192-208.
16. Choi D. W. Bench to bedside: The glutamate connection. Science. 258:1992;241-243.
17. Colton C. A., Pagan F., Snell J., Colton J. S., Cummins A., Gilbert D. L. Protection from oxidation enhances the survival of cultured mesencephalic neurons. Exp. Neurol. 132:1995;54-61.
18. Defer G.-L., Geny C., Ricolfi F., Fenelon G., Montfort J.-C., Remy P., Villafane G., Jeny R., Keravel Y., Gaston A., Degos J.-D., Peschanski M., Cesaro P., Nguyen J. P. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain. 119:1996;41-50.
19. Duan W.-M., Widner H., Brundin P. Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in grafts. Exp. Brain. Res. 104:1995;227-242.
20. Dunnett S. B., Kendall A. L., Watts C., Torres E. M. Neuronal cell transplantation for Parkinson's and Huntington's diseases. British Med. Bull. 53:1997;757-776.
21. Fawcett J. W., Barker R. A., Dunnett S. B. Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp. Brain Res. 106:1995;275-282.
22. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Wells T. H., Barrett J. N., Grafton S. T., Huang S. C., Eidelberg D., Rottenberg D. A. Transplantation of human fetal dopamine cells for Parkinson's disease. Arch. Neurol. 47:1990;505-512.
23. Freed W. J., Perlow M. J., Karoum F., Seiger A., Olson L., Hoffer B. J., Wyatt B. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long-term behavioral, biochemical, and histochemical studies. Ann. Neurol. 8:1980;510-519.
24. Freed W. J., Poltorak M., Takashima H., LaMarca M. E., Ginns E. I. Brain grafts and Parkinson's disease. J. Cell Biochem. 45:1991;261-267.
25. Freeman T. B., Olanow C. W., Hauser R. A., Nauert G. M., Smith D. A., Borlongan C. V., Sandberg P. R., Holt D. A., Kordower J. H., Vingerhoets F. J., Snow B. J., Calne D., Gauger L. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol. 38:1995;379-388.
26. Freeman T. B., Sanberg P. R., Nauert G. M., Boss B. D., Spector D., Olanow C. W., Kordower J. H. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplant. 4:1995;141-154.
27. Frisch S. M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:1994;619-626.
28. Frisch S. M., Ruoslahti E. Integrins and apoptosis. Curr. Op. Cell Biol. 9:1997;701-706.
29. Gavrieli Y., Sherman Y., Ben Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
30. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
31. Heim R. C., Willingham G., Freed W. J. A comparison of solid intraventricular and dissociated intraparenchymal fetal substantia nigra grafts in a rat model of Parkinson's disease: Impaired graft survival is associated with high baseline rotational behavior. Exp. Neurol. 122:1993;5-15.
32. Henderson B. T., Clough C. G., Hughes R. C., Hitchcock E. R., G. B., Kenny B. G. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch. Neurol. 48:1991;822-827.
33. Herman J. P., Abrous N. D. Dopaminergic neural grafts after fifteen years: results and perspectives. Prog. Neurobiol. 44:1994;1-35.
34. Hitchcock E. R., Clough C., Hughes R., Kenny B. Embryos and Parkinson's disease. Lancet. i:1988;1274.
35. Jenner P., Olanow C. W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-84.
36. Kaplan K. S., Brighton C. T., Boytim M. J., Selzer M. E., Lee L., Spindler K., Silberberg D., Black J. Enhanced survival of rat neonatal cerebral cortical neurons at subatmospheric oxygen tensions in vitro. Brain Res. 384:1986;199-203.
37. Kordower J. H., Freeman T. B., Olanow C. W. Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Movement Disorders. 13:1998;88-95.
38. Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J. G., Mufson E. J., Sanberg P. R., Hauser R. A., Smith D. A., Nauert G. M., Perl D. P., Olanow C. W. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New Eng. J. Med. 332:1995;1118-1124.
39. Kordower J. H., Goetz C. G., Freeman T. B., Olanow C. W. Dopaminergic transplants in patients with Parkinson's disease: Neuroanatomical correlates of clinical recovery. Exp. Neurol. 144:1997;41-46.
40. Kordower J. H., Schueler S., Bredesen D., Freeman T. B., Sagen J. Neural grafting for Parkinson's disease: An evaluation of dopaminergic donor tissues. Marwah J., Teitlebaum H., Prasad H. Neural Transplantation, CNS Neuronal Injury, and Regeneration: Recent Advances. 1994;17-37 CRC Press, Boca Raton.
41. Kordower J. H., Styren S., Clarke M., DeKosky S. T., Olanow C. W., Freeman T. B. Fetal grafting for Parkinson's disease: Expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 6:1997;213-219.
42. Letourneau P. C., Condic M. L., Snow D. M. Interactions of developing neurons with the extracellular matrix. J. Neurosci. 14:1994;915-928.
43. Lindvall O. Update on fetal transplantation: The Swedish experience. Movement Disorders. 13:1998;83-87.
44. Lindvall O. Neural transplantation: A hope for patients with Parkinson's disease. NeuroReport. 8:1997;iii-x.
45. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D., Björklund A. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 247:1990;574-577.
46. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Åstedt B., Widner H., Lindholm T., Björklund A., Leenders K. L., Rothwell J. C. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46:1989;615-631.
47. Lopez-Lozano J. J., Bravo G., Brera B., Millan I., Dargallo J., Salmean J., Uria J., Insausti J. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. J. Neurosurg. 86:1997;931-942.
48. Loten E. G., Smith J. A., Jarett L. Activation and inhibition of insulin receptor autophosphorylation by trypsin treatment of intact H35 cells. Int. J. Biochem. 25:1993;653-660.
49. Love R. M., Branton R. L., Clarke D. J. Effects of anaesthetics on survival of rat fetal dopaminergic neurons. Brain Res. Assoc. Abstr. 14:1997;32.
50. Madrazo I., León V., Torres C., Aguilera C., Varela G., Alvarez F., Fraga A., Drucker-Colín R., Ostrosky F., Skurovich M., Franco R. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 318:1988;51.
51. Mahalik T. J., Hahn W. E., Clayton G. H., Owens G. P. Programmed cell death in developing grafts of fetal substantia nigra. Exp. Neurol. 129:1994;27-36.
52. Marsden C. D. Parkinson's disease. Lancet. 335:1990;948-952.
53. Meredith J. E. J., Fazeli B., Schwartz M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4:1993;953-961.
54. Meredith J. E. J., Schwartz M. A. Integrins, adhesion and apoptosis. Trends Cell Biol. 7:1997;146-150.
55. Nakao N., Frodl E. M., Widner H., Carlson E., Eggerding F. A., Epstein C. J., Brundin P. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med. 1:1995;226-231.
56. Nishino H., Czurko A., Fukuda A., Hashitani T., Hida H., Karada Z., Lenard L. Pathophysiological process of transient ischemia of the middle cerebral artery in the rat. Brain Res. Bull. 35:1994;51-56.
57. Olanow C. W., Kordower J. H., Freeman T. B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19:1996;102-109.
58. Oo T. F., Burke R. E. The time course of developmental cell death in phenotypically defined dopaminergic neurons of the substantia nigra. Dev. Brain Res. 98:1997;191-196.
59. Oo T. F., Henchcliffe C., Burke R. E. Apoptosis in substantia nigra following developmental hypoxia-ischemic injury. Neurosci. 69:1995;893-901.
60. Perlow M. J., Freed W. J., Seiger A., Olson L., Wyatt R. J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 204:1979;643-647.
61. Reichardt L. F., Tomaselli J. K. Extracellular matrix molecules and their receptors: Functions in neural development. Annu. Rev. Neurosci. 14:1991;531-570.
62. Rosenstein J. M. Why do neural transplants survive? An examination of some metabolic and pathophysiological considerations in neural transplantation. Exp. Neurol. 133:1995;1-6.
63. Sanberg P. R., Nash D. R., Calderson S. F., Giordano M., Shipley M. T., Norman A. B. Neural transplants disrupt the blood-brain barrier and allow peripherally acting drugs to exert a centrally mediated behavioural effect. Exp. Neurol. 102:1988;149-152.
64. Sautter J., Tseng J. L., Braguglia D., Aebischer P., Spenger C., Seiler R. W., Widmer H. R., Zurn A. D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth and function of fetal dopaminergic grafts. Exp. Neurol. 149:1998;230-236.
65. Schierle G. S., Hansson O., Leist M., Nicotera P., Widner H., Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat. Med. 5:1999;97-100.
66. Sladek J. R. Jr., Collier T. J., Elsworth J. D., Roth R. H., Taylor J. R., Redmond D. E. Jr. Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in nonhuman primates. Cell Transplant. 7:1998;87-96.
67. Sladek J. R. Jr., Elsworth J. D., Roth R. H., Evans L. E., Collier T. J., Cooper S. J., Taylor J. R., Redmond D. E. J. Fetal Dopamine cell survival after transplantation is dramatically improved at a critical donor gestational age in non-human primates. Exp. Neurol. 122:1993;16-27.
68. Sladek J. R. Jr., Redmond D. E. J., Collier T. J., Blount J. P., Elsworth J. D., Taylor J. R., Roth R. H. Fetal dopamine neural grafts: Extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. Prog. Brain Res. 78:1988;497-506.
69. Sortwell C. E., Collier T. J., Sladek J. R. Jr. Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons. J. Comp Neurol. 399:1998;530-540.
70. Thompson S. A., Whiting P. J., Wafford K. A. Barbiturate interactions at the human GABA-A receptor: Dependence on receptor subunit combination. Br. J. Pharmacol. 117:1996;521-527.
71. Yurek D. M., Sladek J. R. Jr. Dopamine cell replacement: Parkinson's disease. Annu. Rev. Neurosci. 13:1990;415-440.
72. Zawada W. M., Zastrow D. J., Clarkson E. D., Adams F. S., Bell K. P., Freed C. R. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 786:1998;96-103.